CraigFredLaForceMD

Allergy & Immunology • Raleigh, NC

Medical Director North Carolina Clinical Research

Join to view full profile

Dr. LaForce is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. LaForce's full profile

Already have an account?

Office
2715 Lake Drive
Raleigh, NC 27607
Phone+1 919-881-0309

Education & Training

University of Colorado School of Medicine/National Jewish Health (Adult)Fellowship, Allergy and Immunology, 1978 - 1980
University of North Carolina HospitalsResidency, Pediatrics, 1975 - 1977
Sidney Kimmel Medical College at Thomas Jefferson UniversityClass of 1975

Certifications & Licensure

NC State Medical License 1980 - 2025
CO State Medical License 1978 - 1983
American Board of Allergy and Immunology Allergy & Immunology
American Board of Pediatrics Pediatrics

Awards, Honors, & Recognition

Regional Top Doctor Castle Connolly, 2014
Fellow (FAAAAI) American Academy of Allergy Asthma and Immunology

Clinical Trials

Study of Lornoxicam or Placebo for Acute Treatment of the Headache of Migraine. Start of enrollment: 2005 Dec 01
Completed
Phase 2
Study of the Effect of Vitamin D as an Add-on Therapy to Corticosteroids in Asthma Start of enrollment: 2011 Apr 01
Completed
Phase 3
Pharmacodynamics, Safety, Tolerability, and Pharmacokinetics of Two Orally Inhaled Indacaterol Salts in Adult Subjects With Asthma. Start of enrollment: 2017 Sep 05
Completed
Phase 2
A Study of Galcanezumab (LY2951742) in Adult Participants With Episodic Migraine Start of enrollment: 2021 Dec 06
Completed
Phase 4
Study to Assess Bronchospasm Potentially Induced by HFO vs HFA MDI in Participants With Well/Partially Controlled Asthma Start of enrollment: 2023 May 02
Completed
Phase 3
A Study Comparing Efficacy, Safety and Tolerability of the Fixed Dose Triple Combination CHF 5993 With the Fixed Dose Dual Combination CHF 1535 in Subjects With COPD Start of enrollment: 2022 Apr 28
Recruiting
Phase 3
Join now to see all

Publications & Presentations

PubMed

9 citations
Pharmacogenetic studies of long-acting beta agonist and inhaled corticosteroid responsiveness in randomised controlled trials of individuals of African descent with as...
Victor E. Ortega, Michelle Daya, Stanley J. Szefler, Eugene R. Bleecker, Vernon M. Chinchilli
The Lancet. Child & Adolescent Health. 2021-11-09
8 citations
Albuterol/budesonide for the treatment of exercise-induced bronchoconstriction in patients with asthma: the TYREE study
Craig LaForce, Bradley E. Chipps, Frank C. Albers, Laurence Reilly, Eva Johnsson
Annals of Allergy, Asthma & Immunology. 2021-10-24
3 citations
Dose-Ranging and Cumulative Dose Studies of Albuterol Sulfate MDI in Co-Suspension Delivery™ Technology (AS MDI; PT007) in Patients with Asthma: the ASPEN and ANTORA T...
Christy Cappelletti, Andrea Maes, Kimberly Rossman, Michael Gillen, Craig LaForce
Clinical Drug Investigation. 2021-06-04

Professional Memberships